Scientific Program Committee

Monday
February 4 Sessions
Session 16 CROI 2008
e Monday, 4-6 pm; Ballroom B/C
Session 16–Symposium CME
Curbing the US Epidemic
Conveners:
Kenneth Mayer, Brown Univ Sch of Med,
Miriam Hosp, Providence, RI, US
Mary Ann Chiasson, Med and Hlth Res Assn
of New York City, NY, US
53
What’s Driving the US Epidemic in Men Who Have
Sex with Men
Ron Stall*, M Friedman, M Marshal, and S Wisniewski
Univ of Pittsburgh Sch of Publ Hlth, PA, US
54
What’s Driving the US Epidemic among Women
Adaora Adimora
Univ of North Carolina at Chapel Hill, US
55
Prevention for Positives
Simon Rosser
Univ of Minnesota, Minneapolis, US
56
Addressing Substance Abuse
David Vlahov
New York Academy of Med, NY, US
Objectives: This session is directed to clinicians and scientists interested
in prevention of HIV infection in the US. It is assumed that participants
are familiar with the groups at highest risk for HIV/AIDS in the US. At
the completion of the session, participants will be knowledgeable about
prevention strategies for men who have sex with men, women at risk, injection
drug users, and persons already infected with HIV.
10 15th Conference on Retroviruses and Opportunistic Infections
e Monday, 4-6 pm; Auditorium
CME
Session 17–Oral Abstracts
Hepatitis Co-infection
Moderators:
Ray Chung, Massachusetts Gen Hosp, Boston, US
Karine Lacombe, Hosp St Antoine, Paris, France
4:00 57 HIV Entry and Replication in Stellate Cells Promotes
Cellular Activation and Fibrogenesis: Implications for
Hepatic Fibrosis in HIV/HCV Co-infection
Ana Tuyama*, F Hong, A Mosoian, P Chen, B Chen, I Fiel,
A Schecter, M Klotman, and M Bansal
Mt Sinai Sch of Med, New York, NY, US
4:15 58 HIV-related Microbial Translocation, a Mechanism for
Liver Disease
A Balagopal1 , F Philp1 , J Astemborski1 , T Block2 , A Mehta2 , G Kirk1 ,
S Mehta1 , A Cox1 , S Ray1 , and David Thomas* 1
1 2 Johns Hopkins Med Inst, Baltimore, MD, US and Drexel Inst for
Biotech and Virology Res, Doylestown, PA, US
4:30 59 Sustained Long-term Antiviral Maintenance with
Pegylated Interferon in HCV/HIV-co-infected Patients:
Early Viral Response and Effect on Fibrosis in Treated
and Control Subjects
Kenneth Sherman* 1 , J Andersen2 , A Butt3 , Z Goodman4 , T Umbleja2 ,
B Alston6 , M Koziel5 , M Peters7 , M Sulkowski8 , R Chung9 , and
ACTG A5178 Study Team
1 2 Univ of Cincinnati, OH, US; Harvard Sch of Publ Hlth, Boston,
MA, US; 3Univ of Pittsburgh, PA, US; 4Armed Forces Inst of
Pathology, Washington, DC, US; 5Beth Israel Deaconess Med
Ctr, Boston, MA, US; 6NIAID, NIH, Bethesda, MD, US; 7Univ of
California, San Francisco, US; 8Johns Hopkins Univ, Baltimore,
MD, US; and 9Massachusetts Gen Hosp, Boston, US
4:45 60 Sustained Virological Response to Interferon plus
Ribavirin Reduces Liver-related Complications and
Mortality in HIV/HCV-co-infected Patients
Juan Berenguer* 1 , J Alvarez-Pellicer2 , J Lopez Aldeguer3 ,
M Von-Wichman4 , C Quereda5 , J Mallolas6 , J Sanz7 , C Tural8 ,
J Bellon1 , J Gonzalez2 , and the GESIDA 3603 Study Group
1 2 Hosp Gregorio Maranon, Madrid, Spain; Hosp La Paz, Madrid,
Spain; 3Hosp La Fe, Valencia, Spain; 4Hosp Donostia, San
Sebastian, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Clin,
Barcelona, Spain; 7Hosp Principe de Asturias, Alcala de Henares,
Madrid; and 8Hosp Germans Trías i Pujol, Badalona, Spain
5:00 61LB Hepatitis C Viremia following Sustained Virological
Response to Pegylated Interferon and Ribavarin in
HIV + Men Who Have Sex with Men–Re-infection or
Late Relapse?
Rachael Jones* 1 , D Brown2 , M Nelson1 , S Bhagani2 , M Atkins1 ,
M Danta3 , G Dusheiko2 , O Pybus4 , and D Asboe1 1 2 Chelsea and Westminster NHS Fndn Trust, London, UK; Royal
Free and Univ Coll Med Sch, London, UK; 3Univ of New South
Wales, Sydney, Australia; and 4Univ of Oxford, UK
5:15 62 3 Interlinked Mechanisms of Inhibition of HIV-1
Reverse Transcriptase by the HBV Drug Entecavir
Egor Tchesnokov* 1 , A Obikhod2 , R Schinazi2 , and M Gotte1 1 2 McGill Univ, Montreal, Canada and Emory Univ Sch of Med,
Atlanta, GA, US
5:30 63 The Anti-HIV Activity of Entecavir: Serum HIV RNA
Decreases and Selection of the M184V Mutation Occurs
in both ART-naïve and -experienced HIV/HBV-coinfected
Individuals
Jennifer Audsley* 1,2,3 , J Sasadeusz1,3 , A Mijch1,2 , R Baden4 , J Caro4,5 ,
H Hunter6 , G Matthews7 , S Olender8 , S Lewin1,2,3 , and C Thio9 1 2 Alfred Hosp, Melbourne, Australia; Monash Univ, Melbourne,
Australia; 3CCREID, Univ of Melbourne, Australia; 4Harvard Med
Sch, Boston, MA, US; 5Fenway Community Hlth, Boston, MA, US;
6 7 AID Atlanta, GA, US; Natl Ctr in HIV Epi and Clin Res, Sydney,
Australia; 8Columbia Univ Med Ctr, New York, NY, US; and 9Johns Hopkins Univ Sch of Med, Baltimore, MD, US
5:45 64 MELD is the Best Predictor of Pre-transplant Mortality
in HIV-infected Liver Transplant Candidates
Aruna Subramanian* 1 , M Sulkowski1 , B Barin2 , D Stablein2 ,
M Curry3 , N Nissen4 , L Dove5 , M Roland6 , P Stock7 , and M Ragni8 1 2 Johns Hopkins Univ, Baltimore, MD US; EMMES Corp, Rockville,
MD, US; 3Beth Israel Deaconess Med Ctr, Boston, MA, US;
4 5 Cedars-Sinai Med Ctr, Los Angeles, CA, US; Columbia Univ, New
York, NY, US; 6California Dept of Publ Hlth, Sacramento, US; 7Univ of California, San Fransisco, US; and 8Univ of Pittsburgh, PA, US